In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.

Abstract

S-1090, a new oral cephalosporin, was active against selected gram-negative bacteria and methicillin-susceptible clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus warneri, against which it had excellent activity. S-1090 was the most active compound against Streptococcus pyogenes and Streptococcus agalactiae among the agents compared. The in vivo efficacy of S-1090 against systemic and urinary and respiratory tract infections caused by gram-positive and -negative bacteria was superior to that expected from the in vitro and in vivo activities of the agents against which it was compared.

• Authors: M Tsuji, Y Ishii, A Ohno, S Miyazaki, K Yamaguchi
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 39 Issue 11 Pg. 2544-51 (Nov 1995) ISSN: 0066-4804 [Print] United States
• PMID: 8585742 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cephalosporins
• S 1090

Topics

• Animals
• Bacteremia (drug therapy, microbiology, prevention & control)
• Bacteria (drug effects)
• Bacterial Infections (drug therapy, microbiology, prevention & control)
• Cephalosporins (pharmacology, therapeutic use)
• Gram-Negative Bacteria (drug effects)
• Gram-Positive Bacteria (drug effects)
• Male
• Mice
• Mice, Inbred ICR
• Microbial Sensitivity Tests
• Respiratory Tract Infections (drug therapy, microbiology, prevention & control)
• Urinary Tract Infections (drug therapy, microbiology)